About us
Board of Directors
Our Team
Incanthera has an experienced and diverse team, operating a lean business model by outsourcing all development work ensuring a low internal fixed cost model.
Stuart Robertson
Chief Executive Officer
Dr Simon Ward
Chief Scientific Officer
Caroline Murray
Non-Executive Director
CEO, Stuart Robertson has a strong history in investment and commercial activities, founding Swiss based global investment company GIFFRIES Technology AG in 2015, acquiring Énielle the subject of our acquisition and portfolio addition announced in June 2026.
Additionally, as founder and Managing Director of Skin and Cell AG in Switzerland since 2023, Stuart manages Incanthera’s manufacturing and commercial relationships in Switzerland and Europe as well as business introduction to commercial contacts globally. Prior to this he was employed at Accenture from 2007 to 2009, CK Hutchison and AS Watson Group from 2002 to 2007, ABB Group from 1997 to 2002 and EY from 1996 to 1997.
Mr Robertson graduated in 1989 from Queensland University of Technology with a BBA. He then completed a MEc Economics at Macquarie University in 1993 and qualified as a Chartered Accountant. He commenced his career at Arthur Andersen in Sydney in 1993 where he gained an MTax in 1995 from Sydney University’s Law School before joining ABB Asea Brown Boveri in Australia in 1997.
Close
Simon is a co-founder of Incanthera and has more than 30 years’ senior experience in academia and business.
He was a founder and CEO of Molecular SkinCare Limited, a pioneer and developer of novel dermatology products for the prevention and management of skin diseases. As CSO of York Pharma plc, he was responsible for bringing innovative dermatology product through to market. Simon also served as chairman of South Yorkshire Bioscience Enterprise Network (SYBEN) and deputy chairman of Medipex, a healthcare innovation hub for NHS organisations across industry and academia internationally.
Simon graduated from the University of London’s School of Pharmacy (UK) with a Joint Honours Degree in Pharmacology and Toxicology and was awarded a DPhil in the Department of Human Anatomy, Oxford University under a Glaxo Group Research Studentship.
Close
Caroline’s expertise across healthcare, market positioning and strategic implementation brings extensive product management, and marketing and commercialisation experience to the Board. Senior positions held in the pharmaceutical industry, including both Novartis and Bristol Myers Squibb, over 30 years, combine dermatology, healthcare and commercial skills, perfectly suited to the company’s goals.
Close
Mr John Howes
Senior Independent Director
With more than 43 years’ experience in UK equity capital markets, John brings a wealth of knowledge and Institutional relationships to Stanford Capital Partners. John has extensive experience in the UK equity capital markets building an established reputation in the small and mid-cap sectors, holding previous positions as Partner with Matrix Corporate Capital and senior positions at Seymour Pierce, Panmure Gordon, Northland Capital and Stanford Capital.
Close
Stuart Robertson
Chief Executive Officer
CEO, Stuart Robertson has a strong history in investment and commercial activities, founding Swiss based global investment company GIFFRIES Technology AG in 2015, acquiring Énielle the subject of our acquisition and portfolio addition announced in June 2026.
Additionally, as founder and Managing Director of Skin and Cell AG in Switzerland since 2023, Stuart manages Incanthera’s manufacturing and commercial relationships in Switzerland and Europe as well as business introduction to commercial contacts globally. Prior to this he was employed at Accenture from 2007 to 2009, CK Hutchison and AS Watson Group from 2002 to 2007, ABB Group from 1997 to 2002 and EY from 1996 to 1997.
Mr Robertson graduated in 1989 from Queensland University of Technology with a BBA. He then completed a MEc Economics at Macquarie University in 1993 and qualified as a Chartered Accountant. He commenced his career at Arthur Andersen in Sydney in 1993 where he gained an MTax in 1995 from Sydney University’s Law School before joining ABB Asea Brown Boveri in Australia in 1997.
Close
Dr Simon Ward
Chief Scientific Officer
Simon is a co-founder of Incanthera and has more than 30 years’ senior experience in academia and business.
He was a founder and CEO of Molecular SkinCare Limited, a pioneer and developer of novel dermatology products for the prevention and management of skin diseases. As CSO of York Pharma plc, he was responsible for bringing innovative dermatology product through to market. Simon also served as chairman of South Yorkshire Bioscience Enterprise Network (SYBEN) and deputy chairman of Medipex, a healthcare innovation hub for NHS organisations across industry and academia internationally.
Simon graduated from the University of London’s School of Pharmacy (UK) with a Joint Honours Degree in Pharmacology and Toxicology and was awarded a DPhil in the Department of Human Anatomy, Oxford University under a Glaxo Group Research Studentship.
Close
Caroline Murray
Non-Executive Director
Caroline’s expertise across healthcare, market positioning and strategic implementation brings extensive product management, and marketing and commercialisation experience to the Board. Senior positions held in the pharmaceutical industry, including both Novartis and Bristol Myers Squibb, over 30 years, combine dermatology, healthcare and commercial skills, perfectly suited to the company’s goals.
Close
Mr John Howes
Senior Independent Director
With more than 43 years’ experience in UK equity capital markets, John brings a wealth of knowledge and Institutional relationships to Stanford Capital Partners. John has extensive experience in the UK equity capital markets building an established reputation in the small and mid-cap sectors, holding previous positions as Partner with Matrix Corporate Capital and senior positions at Seymour Pierce, Panmure Gordon, Northland Capital and Stanford Capital.
Close